Key Concepts for CRNA Interview: DIC, TTP, and Sepsis
Critical Distinction: These Are Different Diseases That Can Look Similar
The most important concept to understand is that DIC and TTP are fundamentally different pathophysiologic processes that both cause thrombocytopenia and microthrombi, but require completely different treatments—confusing them can be fatal. 1, 2
Core Pathophysiology Differences
DIC (Disseminated Intravascular Coagulation):
- All coagulation systems activated simultaneously: coagulation cascade, fibrinolysis, and platelets 2
- Consumption coagulopathy leading to both thrombosis AND bleeding
- Triggered by sepsis, trauma, or other systemic insults through damage-associated molecular patterns (DAMPs) and inflammatory mediators 3
- Results in widespread microvascular thrombosis with hemorrhagic complications from factor consumption
TTP (Thrombotic Thrombocytopenic Purpura):
- Only platelets are markedly activated—coagulation factors remain normal 2
- Caused by severe ADAMTS13 deficiency (<10% activity) 1
- ADAMTS13 normally cleaves von Willebrand factor (VWF); without it, ultra-large VWF multimers cause spontaneous platelet aggregation
- Two types: immune TTP (iTTP) from autoantibodies or congenital TTP (cTTP) from genetic mutations 1
The Diagnostic Challenge in Sepsis
Sepsis can cause BOTH conditions, and approximately 15% of DIC patients may have overlapping TMA features 2. This creates a critical diagnostic dilemma because:
- Sepsis-induced DIC is common (occurs in most severe sepsis cases)
- TTP is rare (1-6 cases per million annually) 4
- Some septic patients develop DIC with secondary ADAMTS13 deficiency, creating a hybrid picture 5
- The key is that true TTP has ADAMTS13 activity <10%, while septic DIC may have reduced but not severely deficient ADAMTS13 1
Diagnostic Approach: The Algorithm You Need
Step 1: Recognize the Clinical Presentation
Both conditions present with:
- Thrombocytopenia
- Microangiopathic hemolytic anemia (MAHA)—look for schistocytes on blood smear
- Organ dysfunction
Key differentiating features:
| Feature | DIC | TTP |
|---|---|---|
| Bleeding | Prominent (oozing, difficult-to-control) [3] | Minimal to absent |
| PT/aPTT | Prolonged | Normal [2] |
| Fibrinogen | Low (consumed) | Normal [2] |
| D-dimer | Markedly elevated | Mildly elevated or normal |
| Hyperfibrinolysis | Present in most cases [2] | Absent |
Step 2: Apply Diagnostic Criteria
For Sepsis-Induced Coagulopathy (SIC)—The Screening Tool:
The SIC score is designed for early detection before overt DIC develops 6:
- Platelet count
- PT-INR
- SOFA score (≥2 required for sepsis diagnosis)
SIC identifies patients at risk with ~30% mortality and high sensitivity for predicting progression to overt DIC 6
For Overt DIC Diagnosis:
Multiple criteria exist (JAAM DIC, ISTH overt-DIC, JSTH DIC) 7, 8. The JAAM criteria are more sensitive and diagnose earlier; ISTH criteria are stricter and diagnose later 7. Choose based on your clinical goal: JAAM for early treatment initiation, ISTH for definitive diagnosis 6.
Step 3: Measure ADAMTS13 Activity
ADAMTS13 activity measurement is the diagnostic gold standard for TTP 4.
- ADAMTS13 <10% = TTP 1
- Send this test immediately if TTP is suspected, but do not wait for results to treat if clinical suspicion is high 4
- Normal or mildly reduced ADAMTS13 with coagulopathy = likely DIC
Treatment: Where Mistakes Kill Patients
If TTP is Suspected (Even Before ADAMTS13 Results)
Initiate the TTP triad immediately 4:
- Plasma exchange (reduced mortality from 15.7% to 3.9% in trials) 4
- Corticosteroids
- Caplacizumab (anti-VWF nanobody)
Add rituximab for immune suppression—modern protocols combining all four therapies have achieved mortality as low as 2.2% compared to 12.2% historically 4
Recombinant ADAMTS13 (Adzynma®) is now available as a newer option 1
If Septic DIC is Diagnosed
Treat the underlying infection first—this is non-negotiable 6, 9, 8
Adjunctive anticoagulant therapy (controversial but recommended in Japanese guidelines):
- Antithrombin: Recommended (GRADE 1B) 8, particularly effective when baseline antithrombin activity ≤43% 6
- Recombinant thrombomodulin: Recommended (GRADE 1B) 8, showed mortality benefit in meta-analyses of DIC patients 6
- Heparin: No clear recommendation due to insufficient evidence 8
The evidence for anticoagulants is debated because large RCTs in "severe sepsis" failed, but post-hoc analyses and meta-analyses in patients specifically with septic DIC showed benefit 6. The key is patient selection—anticoagulants work in DIC, not in sepsis without DIC.
Two-Phase Management in Trauma-Related DIC
If discussing trauma (relevant for perioperative scenarios):
Early phase (hyperfibrinolytic):
- Damage control resuscitation guided by viscoelastic testing (TEG/ROTEM)
- Tranexamic acid for hemorrhage control 10
Late phase (thrombotic):
- VTE prophylaxis
- Consider targeted anticoagulation for microvascular thrombosis 10
Critical Pitfalls to Avoid
Never delay TTP treatment waiting for ADAMTS13 results—mortality was nearly 100% before plasma exchange; survival now exceeds 95% with prompt treatment 1, 4
Don't give plasma exchange for DIC—it's not indicated and wastes resources. DIC needs treatment of underlying cause plus potential anticoagulation 8
Don't use anticoagulants in TTP—the problem is platelet aggregation from VWF, not thrombin generation 1
Recognize that liver dysfunction confounds both DIC and SIC scoring because platelets and PT are affected by hepatic synthetic function 6
Understand that "DIC" in sepsis exists on a spectrum: SIC (early, compensated) → overt DIC (late, decompensated). The two-step approach of screening with SIC then confirming with overt DIC criteria is the pragmatic standard 6
What CRNA Interviewers Want to Hear
Demonstrate you understand:
- The mechanistic difference (ADAMTS13 deficiency vs. systemic coagulation activation)
- Why ADAMTS13 testing is critical when thrombocytopenia + MAHA occur without clear coagulopathy
- That TTP is a medical emergency requiring immediate plasma exchange, not a surgical/anesthetic problem
- How perioperative stress, infection, or trauma can precipitate DIC
- The importance of viscoelastic testing (TEG/ROTEM) in guiding resuscitation in acute DIC
- That you would immediately consult hematology if ADAMTS13 <10% or TTP suspected
The bottom line: In a patient with thrombocytopenia and microangiopathic hemolysis, normal coagulation studies (PT/PTT/fibrinogen) should make you think TTP and call for ADAMTS13 testing and hematology consultation immediately, while abnormal coagulation studies with sepsis/trauma context suggest DIC requiring treatment of the underlying cause plus consideration of anticoagulant therapy.